Clinical Trial: Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071246) titled 'Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis' on July 12, 2022.

Brief Summary: Myasthenia gravis (MG) is the most common acquired disorder of neuromuscular junction (NMJ), the most common antibody (in 85% MG patients) being the nicotinic acetylcholine receptor (AChR). Traditional medical treatments of new-onset MG include anticholinesterase inhibitors, immunomodulating therapies such as intravenous immunoglobulin (IVIG) and plasma exchange (PLEX) and immunosuppressive agents such as corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate and cyclophosphamide. Since a status of complete sta...